Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of tezepelumab in eosinophilic esophagitis (CROSSING)
MOH_2023-02-14_012354Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tezepelumab in eosinophilic esophagitis (EoE) (3 arms), sponsored by AstraZeneca. Started Feb 2023; status: active, not recruiting.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on MOH_2023-02-14_012354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-02-14_012354.